Effects of single-dose praziquantel on morbidity and mortality resulting from intestinal schistosomiasis

East Mediterr Health J. 2000 Sep-Nov;6(5-6):926-31.

Abstract

The long-term effect of single-dose praziquantel on morbidity and mortality from Schistosoma mansoni was investigated in surveys in 1987 and 1994 in central Sudan. Prevalence of infection dropped from 53% to 34%, and intensity of infection (> or = 400 eggs/g of faeces) from 31% to 18%. There was a reduction in hepatomegaly and hepatosplenomegaly, although splenomegaly alone was unchanged. Prevalence of periportal fibrosis decreased from 14% to 10%. Endoscopic investigation of patients with fibrosis showed a reduction in oesophageal varices from 47% to 30%. Mortality due to bleeding varices was high (community-wide, up to 11/100 infected patients with bleeding). Thus praziquantel mass treatment can be spaced to a much longer period, reducing the expense of treatment, delivery and distribution.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Distribution
  • Anthelmintics / pharmacology
  • Anthelmintics / therapeutic use*
  • Cause of Death
  • Child
  • Child, Preschool
  • Endemic Diseases / prevention & control*
  • Endemic Diseases / statistics & numerical data*
  • Esophageal and Gastric Varices / parasitology
  • Hepatomegaly / parasitology
  • Humans
  • Incidence
  • Infant
  • Liver Cirrhosis / parasitology
  • Middle Aged
  • Morbidity
  • Parasite Egg Count
  • Population Surveillance
  • Praziquantel / pharmacology
  • Praziquantel / therapeutic use*
  • Prevalence
  • Schistosomiasis mansoni / complications
  • Schistosomiasis mansoni / diagnosis
  • Schistosomiasis mansoni / drug therapy*
  • Schistosomiasis mansoni / epidemiology*
  • Severity of Illness Index
  • Splenomegaly / parasitology
  • Sudan / epidemiology

Substances

  • Anthelmintics
  • Praziquantel